Lipid nanoparticles have earned their place as the delivery platform of choice for RNA therapeutics. The COVID-19 vaccines proved they could work at global scale, and a growing pipeline of siRNA, mRNA, and gene editing therapies has validated their versatility. But there is a problem the field has been grappling with quietly for years: most LNPs, when administered systemically, end up in the liver. For hepatic indications, that's fine. For everything else, such as T cells, tu